Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Existing shareholders face potential dilution from stock options and restricted stock units awarded to three new employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achieve Life Sciences (ACHV) approved stock options and restricted stock unit awards for three new employees as employment inducements. The grants cover options to purchase 97,000 shares and restricted stock units covering another 97,000 shares. Option exercise prices equal the closing share price on the applicable grant date.
Both awards vest over four years, subject to continued service. Options vest 25% on the first anniversary following employment commencement, with the remaining 75% vesting in 36 equal monthly installments. Restricted stock units vest 25% on each anniversary following employment commencement; each unit provides one common share upon vesting. The grants fall under the 2024 Equity Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.97,000 stock options create potential dilution, with exercise prices equal to grant-date closing share prices.
- Minor point. Forward-looking: it has not happened yet and may not happen.97,000 restricted stock units provide one common share each upon vesting, creating potential dilution.
Details
Market move: ACHV -3.22% vs previous close. new hire inducement awards
On Nov 2, the day this news came out, the latest delayed price for ACHV is 3.22% below the previous close. Our momentum scanner has recorded 11 alerts for this stock so far that day. The latest delayed price is $6.61. Relative volume is elevated at 2.1x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Stock options granted
- 97,000 shares
- Aggregate grant to three new employees
- RSUs granted
- 97,000 shares
- Aggregate award to three new employees
- Option vesting period
- 4 years
- Subject to continued service
- Initial option vesting
- 25%
- Vests on the first anniversary of employment commencement
- Remaining option vesting
- 36 equal monthly installments
- After the first-anniversary vesting
- RSU vesting
- 4 years; 25% on each anniversary
- Subject to continued service
Historical Context
-
Earlier grants under the 2024 Equity Inducement Plan included options and RSUs for new employees and the CFO.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock unit financial
new drug application regulatory
breakthrough therapy designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that the Compensation Committee of Achieve’s Board of Directors approved stock option grants to purchase an aggregate of 97,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 97,000 shares of its common stock for three new employees.
The stock options have an exercise price equal to the closing price of Achieve’s common stock on the applicable grant date. Each stock option has a four-year vesting period and will vest as to
Each RSU award represents the right to receive one share of Achieve’s common stock upon vesting, subject to the recipient’s continued service. The RSUs will vest over four years with
The stock options and RSU awards are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement or RSU award agreement covering the grants and were made as an inducement material to the individuals entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).
About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is an investigational compound that binds to nicotinic receptors. It is being developed as an aid to smoking cessation treatment in adults and as an aid to nicotine e-cigarette cessation.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510
Reference
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What new-hire equity awards did Achieve Life Sciences approve?
Achieve approved options to purchase 97,000 common shares and restricted stock units covering 97,000 common shares for three new employees. The awards were employment inducements under the 2024 Equity Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).